Psoriasis study tests double and quadruple doses for a potential 'Drug Holiday'

This small pilot study tested whether giving higher-than-standard starting doses of the drug risankizumab could lead to better and longer-lasting skin clearance for people with moderate-to-severe plaque psoriasis. Researchers wanted to see if these higher doses could more effectively target specific immune cells in the skin thought to cause psoriasis flare-ups. The goal was to see if patients could potentially stop the drug and maintain clear skin for a longer period.